Skip to main content
Premium Trial:

Request an Annual Quote

WaferGen's Q2 Revenues Drop Sharply

NEW YORK (GenomeWeb News) – WaferGen reported after the close of the market Monday that revenues for the second quarter slid nearly 10-fold year over year due to an "absence of sales" of its flagship real-time PCR platform.

For the three months ended June 30, the Fremont, Calif.-based firm posted revenues of $44,905, down from $431,894 a year ago, a drop that it attributed to the absence of sales of its SmartChip Real-time PCR Systems, as well as a decrease in sales of its Real-time PCR Chip panels and fee-for-service.

WaferGen posted a net loss of $9.2 million, or $.45 per share, for the second quarter, compared to a profit of $724,496, or $.02 per share, a year ago.

The firm's R&D costs rose 33 percent year over year to $2 million from $1.5 million due to expenses associated with the development of SmartChip products and services. Its SG&A costs shot up 81 percent to $2.9 million from $1.6 million, the result of additional staffing, activities related to the commercialization and sales of SmartChip products, consulting expenses, and fundraising activities.

During the quarter, the company took a non-cash charge of $13.2 million related to a $30.6 million private placement that it completed in June. It also saw a net loss from warrant derivative revaluations of $191,000 during the quarter, compared to a gain of $3.6 million a year ago, WaferGen said.

Alnoor Shivji, chairman and CEO of the company, said in a statement that the primary focus during the quarter was to secure funding for further commercialization of the SmartChip Real-Time PCR System, launched a year ago. Having achieved that with the $30.6 million private placement, "We will put this money to work … to expand the commercial team and generate additional applications and content for the SmartChip System," he said.

"With additional applications (genotyping) and enhancements to SmartChip panels … we can continue to enrich the transformative SmartChip System to address unmet needs in biomarker profiling validation, next-generation sequencing validation, disease research, drug development, personalized medicine and applied markets," Shivji added.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.